$CYDY
CytoDyn Inc. Stock $cydy

$cydy Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000155837023015718 Filed on September 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue	$0.00	$0.00	$20.63M
YoY Change	-100.0%	-100.0%	38830.19%
Gross Profit	$0.00	$0.00	-$20.63M
YoY Change	-100.0%	-100.0%	-9786.85%
Gross Profit Margin
Selling, General & Admin	$2.688M	$2.789M	$17.14M
YoY Change	-57.56%	-73.03%	-61.32%
% of Gross Profit
Research & Development	$1.914M	$981.0K	$2.632M
YoY Change	232.29%	-119.98%	-90.27%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K	$175.0K
YoY Change	-89.9%	-91.94%	-77.59%
% of Gross Profit
Operating Expenses	$1.914M	$3.780M	$2.632M
YoY Change	232.29%	-31.99%	-90.27%
Operating Profit	-$4.612M	-$3.780M	-$40.58M
YoY Change	-52.51%	-95.22%	-72.09%
Interest Expense	-$1.959M	-$11.27M	-$25.25M
YoY Change	-81.05%	408.66%	66.61%
% of Operating Profit
Other Income/Expense, Net	-$912.0K	-$928.0K	-$8.689M
YoY Change	-2.98%	-1.8%	-3.77%
Pretax Income	-$11.57M	-$18.64M	-$79.82M
YoY Change	-44.88%	-83.12%	-62.14%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.57M	-$18.64M	-$79.82M
YoY Change	-44.88%	-83.12%	-62.14%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01		-$0.10
Diluted Earnings Per Share	-$0.01	-$0.02	-$0.10
COMMON SHARES
Basic Shares Outstanding	931.0M		836.5M
Diluted Shares Outstanding	923.6M		836.5M

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.034M	$2.541M	$2.541M
YoY Change	-56.5%	-39.94%	-39.94%
Cash & Equivalents	$2.034M	$2.541M
Short-Term Investments
Other Short-Term Assets	$9.934M	$8.264M	$8.264M
YoY Change	91.74%	31.51%	31.51%
Inventory		$0.00
Prepaid Expenses	$2.858M	$1.167M
Receivables
Other Receivables
Total Short-Term Assets	$11.97M	$10.81M	$10.81M
YoY Change	21.42%	2.76%	-62.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$366.0K	$400.0K	$400.0K
YoY Change	-27.09%	447.95%	-34.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$443.0K	$487.0K	$87.00K
YoY Change	-27.14%	-34.28%
Total Long-Term Assets	$443.0K	$487.0K	$487.0K
YoY Change	-97.61%	-97.39%	-34.28%
TOTAL ASSETS
Total Short-Term Assets	$11.97M	$10.81M	$10.81M
Total Long-Term Assets	$443.0K	$487.0K	$487.0K
Total Assets	$12.41M	$11.29M	$11.29M
YoY Change	-56.29%	-61.31%	-61.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$62.80M	$62.70M	$62.73M
YoY Change	-8.99%	-7.79%	-7.72%
Accrued Expenses	$26.23M	$22.58M	$22.58M
YoY Change	59.02%	19.15%	19.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$33.10M	$34.42M	$34.42M
YoY Change	-10.13%	-5.03%	-5.03%
Total Short-Term Liabilities	$129.1M	$119.8M	$119.8M
YoY Change	5.51%	-2.73%	-2.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$714.0K	$714.0K
YoY Change
Other Long-Term Liabilities	$247.0K	$283.0K	$283.0K
YoY Change	-36.18%	-32.94%	-32.94%
Total Long-Term Liabilities	$247.0K	$997.0K	$997.0K
YoY Change	-36.18%	136.26%	136.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$129.1M	$119.8M	$119.8M
Total Long-Term Liabilities	$247.0K	$997.0K	$997.0K
Total Liabilities	$129.3M	$120.8M	$120.8M
YoY Change	5.37%	-2.26%	-2.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$853.3M	-$841.7M
YoY Change	9.0%	9.87%
Common Stock	$931.0K	$919.0K
YoY Change	14.51%	27.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$116.9M	-$109.5M	-$109.5M
YoY Change
Total Liabilities & Shareholders Equity	$12.41M	$11.29M	$11.29M
YoY Change	-56.29%	-61.31%	-61.31%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$11.57M	-$18.64M	-$79.82M
YoY Change	-44.88%	-83.12%	-62.14%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$175.0K
YoY Change	-89.9%	-91.94%	-77.59%
Cash From Operating Activities	-$4.495M	-$3.412M	-$25.11M
YoY Change	-59.41%	-43.55%	-67.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.019M	1.350M	29.93M
YoY Change	-65.11%	-82.87%	-37.67%
NET CHANGE
Cash From Operating Activities	-4.495M	-3.412M	-25.11M
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	4.019M	1.350M	29.93M
Net Change In Cash	-476.0K	-2.062M	4.817M
YoY Change	-206.97%	-210.39%	-116.21%
FREE CASH FLOW
Cash From Operating Activities	-$4.495M	-$3.412M	-$25.11M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	836528000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	676900000
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001175680
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.cytodyn.com/20230531#AccruedCompensationAndNonFinancingLiabilities
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0
CY2023	dei	Entity Registrant Name EntityRegistrantName	CytoDyn Inc.
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2022Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.cytodyn.com/20230531#AccruedCompensationAndNonFinancingLiabilities
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-05-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-49908
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1887078
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Main Street, Suite 660
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Vancouver
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98660
CY2023	dei	City Area Code CityAreaCode	360
CY2023	dei	Local Phone Number LocalPhoneNumber	980-8524
CY2023	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2023	dei	Security12g Title Security12gTitle	Common Stock, par value $0.001 per share
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	295738201
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	930960097
CY2023	dei	Auditor Firm AuditorFirmId	324
CY2023	dei	Auditor Firm AuditorFirmId	324
CY2023	dei	Auditor Name AuditorName	Macias Gini & O’Connell LLP
CY2023	dei	Auditor Name AuditorName	Macias Gini & O’Connell LLP
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2541000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4231000
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6507000
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1167000
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5198000
CY2023Q2	cydy	Prepaid Service Fees Current PrepaidServiceFeesCurrent	590000
CY2022Q2	cydy	Prepaid Service Fees Current PrepaidServiceFeesCurrent	1086000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	10805000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	10515000
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	17929000
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	487000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	741000
CY2023Q2	us-gaap	Assets Assets	11292000
CY2022Q2	us-gaap	Assets Assets	29185000
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	62725000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	67974000
CY2023Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	6669000
CY2022Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	8995000
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	10598000
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	5974000
CY2023Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	5308000
CY2022Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	3977000
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	34417000
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	36241000
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	79000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	119796000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	123161000
CY2023Q2	us-gaap	Notes Payable NotesPayable	714000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	422000
CY2023Q2	us-gaap	Liabilities Liabilities	120793000
CY2022Q2	us-gaap	Liabilities Liabilities	123583000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1350000000
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1350000000
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	919053000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	720028000
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	918610000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	719585000
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	919000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	720000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	443000
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	443000
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	731270000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	671013000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-841690000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-766131000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-109501000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-94398000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11292000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29185000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	53000
CY2022	us-gaap	Gross Profit GrossProfit	213000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17136000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44303000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2632000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27043000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	175000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	781000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	20633000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	73490000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	40576000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	145617000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40576000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-145404000
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4624000
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	5417000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2126000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2958000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	9747000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	87000
CY2023	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	5312000
CY2022	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	37381000
CY2023	cydy	Finance Charge Adjustments FinanceChargeAdjustments	8689000
CY2022	cydy	Finance Charge Adjustments FinanceChargeAdjustments	9029000
CY2022	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	6691000
CY2022	cydy	Non Operating Legal Settlement Expense NonOperatingLegalSettlementExpense	-3853000
CY2023	cydy	Gain Loss On Derivatives GainLossOnDerivatives	-8750000
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense	39248000
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	65416000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79824000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-210820000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79824000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-210820000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	836528000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	676900000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-21018000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	68381000
CY2022	cydy	Issuance Of Stock Value Legal Settlement IssuanceOfStockValueLegalSettlement	2863000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	390000
CY2022	cydy	Stock Issued For Incentive Compensation And Tendered For Income Tax Value StockIssuedForIncentiveCompensationAndTenderedForIncomeTaxValue	668000
CY2022	cydy	Offering Costs Related To Stock Issuance OfferingCostsRelatedToStockIssuance	-5316000
CY2022	cydy	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1036000
CY2022	cydy	Inducement Interest Expense Related To Private Warrant Exchange InducementInterestExpenseRelatedToPrivateWarrantExchange	6691000
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1330000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5571000
CY2022	cydy	Adjustments To Additional Paid In Capital Warrant Issuance Cost AdjustmentsToAdditionalPaidInCapitalWarrantIssuanceCost	6585000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-210820000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-94398000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4000000
CY2023	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	5312000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	114000
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	985000
CY2023	cydy	Offering Costs Related To Stock Issuance OfferingCostsRelatedToStockIssuance	-1760000
CY2023	cydy	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	439000
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1331000
CY2023	cydy	Reclassification Of Warrants From Liability To Equity Classified ReclassificationOfWarrantsFromLiabilityToEquityClassified	8756000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3290000
CY2023	cydy	Adjustments To Additional Paid In Capital Warrant Issuance Cost AdjustmentsToAdditionalPaidInCapitalWarrantIssuanceCost	4885000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79824000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-109501000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79824000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-210820000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	175000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	781000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	9747000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	87000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2126000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2958000
CY2022	cydy	Adjustment To Reconcile Net Loss To Net Cash Used In Operating Activities Litigation Settlement AdjustmentToReconcileNetLossToNetCashUsedInOperatingActivitiesLitigationSettlement	3663000
CY2023	cydy	Finance Charges Related To Surety Bond FinanceChargesRelatedToSuretyBond	4885000
CY2022	cydy	Finance Charges Related To Surety Bond FinanceChargesRelatedToSuretyBond	6585000
CY2023	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-8750000
CY2023	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	5312000
CY2022	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	37381000
CY2022	cydy	Inducement Interest Expense And Non Cash Finance Charges InducementInterestExpenseAndNonCashFinanceCharges	6691000
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-6000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	20633000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	73490000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4275000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6239000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2060000
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1902000
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4125000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3097000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2713000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25110000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77723000
CY2023	cydy	Proceeds From Warrant Transactions Net ProceedsFromWarrantTransactionsNet	2807000
CY2022	cydy	Proceeds From Warrant Transactions Net ProceedsFromWarrantTransactionsNet	5390000
CY2023	cydy	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	25786000
CY2022	cydy	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	41195000
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	439000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1036000
CY2023	cydy	Proceeds From Convertible Note And Warrant Issuances ProceedsFromConvertibleNoteAndWarrantIssuances	895000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	390000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29927000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48011000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4817000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29712000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4231000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33943000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9048000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4231000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2541000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4231000
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6507000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9048000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4231000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	19000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	63000
CY2023	cydy	Noncash Derivative Liability Associated With Warrants NoncashDerivativeLiabilityAssociatedWithWarrants	8750000
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4000000
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	31000000
CY2023	cydy	Dividends On Convertible Preferred Stock Incurred But Not Yet Paid. DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.	1490000
CY2022	cydy	Dividends On Convertible Preferred Stock Incurred But Not Yet Paid. DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.	1636000
CY2022	cydy	Stock Issued During Period Non Cash Value Warrant Exercised StockIssuedDuringPeriodNonCashValueWarrantExercised	1000
CY2023	cydy	Dividend Declared And Paid In Common Stock DividendDeclaredAndPaidInCommonStock	159000
CY2022	cydy	Dividend Declared And Paid In Common Stock DividendDeclaredAndPaidInCommonStock	305000
CY2023	cydy	Warrants Issued To Placement Agent Recorded In Additional Paid In Capital WarrantsIssuedToPlacementAgentRecordedInAdditionalPaidInCapital	7640000
CY2022	cydy	Warrants Issued To Placement Agent Recorded In Additional Paid In Capital WarrantsIssuedToPlacementAgentRecordedInAdditionalPaidInCapital	3597000
CY2023	cydy	Warrants Issued For Surety Bond Backstop Agreement WarrantsIssuedForSuretyBondBackstopAgreement	4885000
CY2022	cydy	Warrants Issued For Surety Bond Backstop Agreement WarrantsIssuedForSuretyBondBackstopAgreement	6585000
CY2023Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	5417000
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;font-weight:normal;">Reclassifications</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Certain prior year amounts shown in the accompanying consolidated financial statements have been reclassified to conform to the current period presentation. Such reclassifications did not have a material effect, if any, on the Company’s previously reported financial position, results of operations, stockholders’ (deficit) equity, or net cash provided by operating activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the fiscal year ended May 31, 2023, the Company reclassified amounts recorded as accumulated dividends for Series C and D preferred stockholders from accumulated deficit to additional paid-in capital. These reclassifications were made to reflect the proper presentation for accrued dividends when an entity has accumulated deficit.</p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79800000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-210800000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-841700000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;font-weight:normal;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The preparation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP” or “GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates are assessed each period and updated to reflect current information, such as the status of our analysis of the results of our clinical trials and/or discussions with the FDA, which could have an impact on the Company’s significant accounting estimates and assumptions. The Company’s estimates are based on historical experience and on various markets and other relevant, appropriate assumptions. Significant estimates include, but are not limited to, those relating to capitalization of pre-launch inventories, charges for excess and obsolete inventories, research and development expenses, commitments and contingencies, stock-based compensation, and the assumptions used to value warrants and warrant modifications. Actual results could differ from these estimates. </p>
CY2022Q2	cydy	Accrued Interest Noncurrent AccruedInterestNoncurrent	5974000
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	45729000
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2300000
CY2023Q2	cydy	Restricted Cash Uninsured Amount RestrictedCashUninsuredAmount	5500000
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	4000000.0
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6500000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	300000
CY2022Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2023Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0
CY2022	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0
CY2023	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	42215000
CY2022Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	42215000
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	696000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2195000
CY2023	cydy	Interest Expense Accrued InterestExpenseAccrued	4624000
CY2023	cydy	Debt Conversion Fair Market Value Of Shares Exchanged For Repayment DebtConversionFairMarketValueOfSharesExchangedForRepayment	5312000
CY2023	cydy	Changes In Fair Value Of Common Stocks Of Convertible Debt ChangesInFairValueOfCommonStocksOfConvertibleDebt	-1311000
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	45729000
CY2023	cydy	Adjustments To Additional Paid In Capital Warrants Modification Induced Warrant Exercise Cost AdjustmentsToAdditionalPaidInCapitalWarrantsModificationInducedWarrantExerciseCost	2200000
CY2023	us-gaap	Dividends Sharebased Compensation Stock DividendsSharebasedCompensationStock	5400000
CY2022Q2	cydy	Inventory Raw Material Noncurrent InventoryRawMaterialNoncurrent	16264000
CY2022Q2	cydy	Inventory Work In Progress Noncurrent InventoryWorkInProgressNoncurrent	1665000
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	17929000
CY2023	cydy	Inventory Number Of Batches Not Saleable InventoryNumberOfBatchesNotSaleable	5
CY2023	cydy	Total Number Of Batches Not Saleable TotalNumberOfBatchesNotSaleable	9
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	73500000
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	2700000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3520000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3520000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3520000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3388000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	132000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000
CY2021Q1	cydy	Acquisition Of Intangible Asset Shares Subject To Arbitration AcquisitionOfIntangibleAssetSharesSubjectToArbitration	3100000
CY2021Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	10000000.0
CY2021Q1	cydy	Impairment Of Intangible Assets Portion Charged Against Original Cost ImpairmentOfIntangibleAssetsPortionChargedAgainstOriginalCost	12200000
CY2021Q1	cydy	Impairment Of Intangible Assets Reversal Of Accumulated Amortization ImpairmentOfIntangibleAssetsReversalOfAccumulatedAmortization	2200000
CY2022Q2	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	800000
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	62700000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	68000000.0
CY2022Q2	cydy	Number Of Counterparties NumberOfCounterparties	2
CY2023Q2	cydy	Number Of Counterparties NumberOfCounterparties	2
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	335000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1522000
CY2023Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	168000
CY2022Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2006000
CY2023Q2	cydy	Accrued Clinical Expenses AccruedClinicalExpenses	187000
CY2022Q2	cydy	Accrued Clinical Expenses AccruedClinicalExpenses	3727000
CY2023Q2	cydy	Accrued Inventory Charges Current AccruedInventoryChargesCurrent	4978000
CY2022Q2	cydy	Accrued Inventory Charges Current AccruedInventoryChargesCurrent	1392000
CY2023Q2	cydy	Accrued License Fees Current AccruedLicenseFeesCurrent	862000
CY2022Q2	cydy	Accrued License Fees Current AccruedLicenseFeesCurrent	150000
CY2023Q2	cydy	Accrued Lease Payable AccruedLeasePayable	139000
CY2022Q2	cydy	Accrued Lease Payable AccruedLeasePayable	134000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	64000
CY2023Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	6669000
CY2022Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	8995000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-841700000
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	36450000
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	38319000
CY2023Q2	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	1319000
CY2022Q2	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	2078000
CY2023Q2	cydy	Long Term Debt Including Accrued Interest LongTermDebtIncludingAccruedInterest	35131000
CY2022Q2	cydy	Long Term Debt Including Accrued Interest LongTermDebtIncludingAccruedInterest	36241000
CY2023Q2	cydy	Accrued Interest Noncurrent AccruedInterestNoncurrent	10598000
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	3400000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000.0
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1350000000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8800000
CY2023Q2	cydy	Warrant Becoming Liability WarrantBecomingLiability	-16664000
CY2023	cydy	Warrant Equity Classified WarrantEquityClassified	25335000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8750000
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	79000
CY2023	cydy	Share Based Compensation Number Of Active Plans ShareBasedCompensationNumberOfActivePlans	1
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.992
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.127
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.943
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.220
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.0706
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.0489
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0383
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0167
CY2023Q2	cydy	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfSharesOutstanding	12000000.0
CY2022Q2	cydy	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfSharesOutstanding	9900000
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	7800000
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	7500000
CY2022Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2800000
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	71100000
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.50
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2000000.0
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P10Y
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	400000
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	42934
CY2021Q2	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice	0.68
CY2021	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm	P2Y10M20D
CY2021Q2	cydy	Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue	52671000
CY2022	cydy	Class Of Warrants Or Rights Granted ClassOfWarrantsOrRightsGranted	38220
CY2022Q2	cydy	Class Of Warrants Or Rights Granted Weighted Average Exercise Price ClassOfWarrantsOrRightsGrantedWeightedAverageExercisePrice	0.52
CY2022	cydy	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	5167
CY2022Q2	cydy	Class Of Warrants Or Rights Exercised Weighted Average Exercise Price ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice	0.70
CY2022	cydy	Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value Exercised ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValueExercised	5514000
CY2022	cydy	Class Of Warrants Or Rights Forfeited Expired And Cancelled ClassOfWarrantsOrRightsForfeitedExpiredAndCancelled	2740
CY2022Q2	cydy	Class Of Warrants Or Rights Forfeited Expired And Cancelled Weighted Average Exercise Price ClassOfWarrantsOrRightsForfeitedExpiredAndCancelledWeightedAverageExercisePrice	0.73
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	73248
CY2022Q2	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice	0.59
CY2022	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm	P3Y2M4D
CY2022Q2	cydy	Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue	352000
CY2023	cydy	Class Of Warrants Or Rights Granted ClassOfWarrantsOrRightsGranted	201771
CY2023Q2	cydy	Class Of Warrants Or Rights Granted Weighted Average Exercise Price ClassOfWarrantsOrRightsGrantedWeightedAverageExercisePrice	0.33
CY2023	cydy	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	6207
CY2023Q2	cydy	Class Of Warrants Or Rights Exercised Weighted Average Exercise Price ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice	0.63
CY2023	cydy	Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value Exercised ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValueExercised	758000
CY2023	cydy	Class Of Warrants Or Rights Forfeited Expired And Cancelled ClassOfWarrantsOrRightsForfeitedExpiredAndCancelled	8902
CY2023Q2	cydy	Class Of Warrants Or Rights Forfeited Expired And Cancelled Weighted Average Exercise Price ClassOfWarrantsOrRightsForfeitedExpiredAndCancelledWeightedAverageExercisePrice	0.75
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	259910
CY2023Q2	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice	0.37
CY2023	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm	P4Y6M25D
CY2023Q2	cydy	Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue	7276000
CY2023	cydy	Class Of Warrant Or Right Outstanding And Exercisable ClassOfWarrantOrRightOutstandingAndExercisable	259910
CY2023Q2	cydy	Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Exercise Price ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageExercisePrice	0.37
CY2023	cydy	Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageRemainingContractualTerm	P4Y6M25D
CY2023Q2	cydy	Class Of Warrants Or Rights Outstanding And Exercisable Aggregate Intrinsic Value ClassOfWarrantsOrRightsOutstandingAndExercisableAggregateIntrinsicValue	7276000
CY2023	cydy	Number Of Warrants Expiration Extended NumberOfWarrantsExpirationExtended	3800000
CY2023	cydy	Adjustment To Additional Paid In Capital Deemed Dividend AdjustmentToAdditionalPaidInCapitalDeemedDividend	600000
CY2023	cydy	Stock Issued During Period Shares Warrants Exercised Cash StockIssuedDuringPeriodSharesWarrantsExercisedCash	1800000
CY2023	cydy	Stock Issued During Period Value Warrants Exercised Cash StockIssuedDuringPeriodValueWarrantsExercisedCash	400000
CY2023	cydy	Stock Issued During Period Non Cash Shares Warrant Exercised StockIssuedDuringPeriodNonCashSharesWarrantExercised	100000
CY2023	cydy	Warrants Exercised Noncash Number Of Warrants WarrantsExercisedNoncashNumberOfWarrants	300000
CY2022	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterest	-0.005
CY2023	cydy	Effective Income Tax Rate Reconciliation Inducement Charge EffectiveIncomeTaxRateReconciliationInducementCharge	0
CY2022	cydy	Effective Income Tax Rate Reconciliation Inducement Charge EffectiveIncomeTaxRateReconciliationInducementCharge	-0.007
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.011
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79824000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-210820000
CY2023	cydy	Deemed Dividend Down Round Feature Decrease In Net Income To Common Shareholder Amount DeemedDividendDownRoundFeatureDecreaseInNetIncomeToCommonShareholderAmount	5417000
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1495000
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1628000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-86736000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-212448000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	836528000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	676900000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	cydy	Effective Income Tax Rate Reconciliation Derivative Gain Loss Percent EffectiveIncomeTaxRateReconciliationDerivativeGainLossPercent	-0.023
CY2022	cydy	Effective Income Tax Rate Reconciliation Derivative Gain Loss Percent EffectiveIncomeTaxRateReconciliationDerivativeGainLossPercent	0
CY2023	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt Issuance Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtIssuanceCostsPercent	-0.026
CY2022	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt Issuance Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtIssuanceCostsPercent	0
CY2023	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterest	-0.012
CY2023	cydy	Effective Income Tax Rate Reconciliation Tax Credit Carryforward EffectiveIncomeTaxRateReconciliationTaxCreditCarryforward	0
CY2022	cydy	Effective Income Tax Rate Reconciliation Tax Credit Carryforward EffectiveIncomeTaxRateReconciliationTaxCreditCarryforward	-0.002
CY2023	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Loss On Induced Conversion Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnInducedConversionPercent	-0.014
CY2022	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Loss On Induced Conversion Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnInducedConversionPercent	-0.037
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	-0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	-0.003
CY2023	cydy	Effective Income Tax Rate Reconciliation Non Deductible Expense Irc162 Limitation EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseIrc162Limitation	0
CY2022	cydy	Effective Income Tax Rate Reconciliation Non Deductible Expense Irc162 Limitation EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseIrc162Limitation	-0.001
CY2023	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense On Induced Conversion Of Debt EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOnInducedConversionOfDebt	0
CY2022	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense On Induced Conversion Of Debt EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOnInducedConversionOfDebt	-0.003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.137
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.163
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	96338000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	106965000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2063000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2063000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	6400000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	6057000
CY2023Q2	cydy	Charitable Contribution Carry Forward CharitableContributionCarryForward	0
CY2022Q2	cydy	Charitable Contribution Carry Forward CharitableContributionCarryForward	14000
CY2023Q2	cydy	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Vacation And Payroll Expenses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedVacationAndPayrollExpenses	21000
CY2022Q2	cydy	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Vacation And Payroll Expenses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedVacationAndPayrollExpenses	68000
CY2023Q2	cydy	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	84000
CY2022Q2	cydy	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	112000
CY2023Q2	cydy	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	89000
CY2022Q2	cydy	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	117000
CY2023Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	6173000
CY2022Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2138000
CY2023Q2	cydy	Inventory Write Off InventoryWriteOff	13739000
CY2022Q2	cydy	Inventory Write Off InventoryWriteOff	0
CY2023Q2	cydy	Deferred Tax Assets Warrants Issuance DeferredTaxAssetsWarrantsIssuance	2317000
CY2022Q2	cydy	Deferred Tax Assets Warrants Issuance DeferredTaxAssetsWarrantsIssuance	0
CY2023Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	858000
CY2022Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	13000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	0
CY2023Q2	cydy	Deferred Tax Assets Accrued Legal Fees DeferredTaxAssetsAccruedLegalFees	3000
CY2022Q2	cydy	Deferred Tax Assets Accrued Legal Fees DeferredTaxAssetsAccruedLegalFees	0
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	36000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	89000
CY2023Q2	cydy	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	609000
CY2022Q2	cydy	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	238000
CY2023Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	4000
CY2022Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128579000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	117638000
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	128579000
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	117638000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128579000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	117638000
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	458800000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	509400000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	200000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	200000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	536000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	139000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	422000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	422000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	556000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	182000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	185000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	169000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	536000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	114000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	422000
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100

Files In Submission

Name	View Source	Status
0001558370-23-015718-index-headers.html	Edgar Link	pending
0001558370-23-015718-index.html	Edgar Link	pending
0001558370-23-015718.txt	Edgar Link	pending
0001558370-23-015718-xbrl.zip	Edgar Link	pending
cydy-20230531.xsd	Edgar Link	pending
cydy-20230531x10k.htm	Edgar Link	pending
cydy-20230531x10k004.jpg	Edgar Link	pending
cydy-20230531xex21.htm	Edgar Link	pending
cydy-20230531xex23.htm	Edgar Link	pending
cydy-20230531xex31d1.htm	Edgar Link	pending
cydy-20230531xex31d2.htm	Edgar Link	pending
cydy-20230531xex32.htm	Edgar Link	pending
cydy-20230531xex4d1.htm	Edgar Link	pending
cydy-20230531xex4d19.htm	Edgar Link	pending
cydy-20230531xex4d20.htm	Edgar Link	pending
cydy-20230531x10k_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
cydy-20230531_def.xml	Edgar Link	unprocessable
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cydy-20230531_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cydy-20230531_cal.xml	Edgar Link	unprocessable
cydy-20230531_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYDY
CytoDyn Inc. Stock $cydy

2023 Q3 Form 10-K Financial Statement

#000155837023015718 Filed on September 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYDY CytoDyn Inc. Stock $cydy

2023 Q3 Form 10-K Financial Statement

#000155837023015718 Filed on September 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYDY
CytoDyn Inc. Stock $cydy